AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITPJames B. Bussel, Janet L. Nichol, David J. Kuter et al.|New England Journal of Medicine|2006Cited by 530
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Christine M. Lovly, Jorge J. Nieva et al.|Journal of Thoracic Oncology|2019Cited by 163
Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.David J. Kuter, Janet L. Nichol, James B. Bussel et al.|Blood|2006Cited by 30
Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.James B. Bussel, Janet L. Nichol, David J. Kuter et al.|Blood|2005Cited by 23
A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).David J. Kuter, Janet L. Nichol, Alan Lichtin et al.|Blood|2004Cited by 17